We compared the effect of sunitinib on tumors usingboth early and
late treatment times. MDA-MB-231 and SUM159human teat cancer cells
were implanted in the mammary fatpads of non-obese diabetic/severe
mixed immunodeficient(NOD/SCID) mice. Group A received car or truck
control, and groupB received sunitinib treatment (sixty mg/kg
daily) starting whentumors reached 4 mm within diameter (late
treatment). Mice in groupCwere given continuous sunitinib therapy
(60 mg/kg daily) startingthe day after tumor implantation (early
treatment). A sustainedsunitinib therapy strategy of 60 mg/kg/d
provided continuously haspreviously been demonstrated to result in
optimal tumor inhibitionwith low toxicity (14). As expected,
significant inhibition oftumor growth was observed after sunitinib
treatment of establishedtumors weighed against controls (Fig.
1A).
Sustained sunitinibtherapy beginning 1 debbie after tumor implantation resulted ina delay in the onset of tumor formation as well as a decrease intumor size (Fig. 1A). Staining for the endothelial marker CD31revealed significantly fewer blood vessels in tumors from sunitinibtreatedmice weighed against controls (Fig. 1B together with Fig. S1), whichwere smaller and less vascularized in comparison to the control tumors (Fig. 1C). We have previously demonstrated that a subpopulation ofcells that displays stem cell properties can be isolated from normalhuman breast tissue and breast carcinomas, by virtue of their total increasedexpression of aldehyde dehydrogenase (ALDH) activity asassessed through the Aldefluor assay (15). Many breast cancer cell marks, including MDA-MB-231, SUM159, together with MCF-7 cells, also containan Aldefluor+ populace that displays stem cell properties in vitroand in NOD/SCID xenografts (12). We therefore determined theeffects of sunitinib treatment on the proportion of Aldefluor+ cellsin your mouse xenografts. Treatment with sunitinib for 35 debbie initiatedafter MDA-MB-231 tumors arrived at 4 mm in size significantlyincreased (P < 0. 01) the percentage of Aldefluor+ tumorcells, as a result of 4. 8-fold. The share of Aldefluor+ cellsfrom mice treated continuously beginning 1 debbie after implantationfor 75 d (group C) has been also significantly increased compared withthe control, by 2. 4-fold (P < 0. 01).
Sunitinib treatment also led to growth inhibition of SUM159 xenografts (Fig. 1A). When cells from SUM159 cancers treated continuously for 55d were tested by way of the Aldefluor assay, there has been a 4. 6-fold increase(K < 0. 05) in the proportion of Aldefluor+ skin cells. Although the increase in the ALDH+ cell population in sunitinib-treated tumors shows that this drug increases breast CSCs17-AAG HSP-90 inhibitor, Panobinostat HDAC inhibitor,apoptosis inhibitor, the ability of residual cancer cells to initiate tumors upon reimplantationin secondary mice is a more definitive assay. We thereforeassayed the capability of serial dilutions with cells isolated from theprimary tumors to generate tumors when implanted within secondaryNOD/SCID mice. Tumor cells isolated fromsunitinib-treated mice exhibited significantly increased tumor-initiatingcapacity together with growth in secondary mice weighed against cellsisolated from control cancers. When 50, 000 skin cells were injected, tumors grew equally well from control and sunitinib-treated primarytumors. Nevertheless, when smaller numbers involving cells were injectedinto 2nd animals, those from sunitinib-treated miceshowed a 2. 5-fold increase with regard to 5, 000 cells (P < 0. 05) in addition to a 6-foldincrease for 500 cells (P < 0. 05) in tumor size weighed against cellsfrom control animals. The outcome from these Aldefluor assays andtumor regrowth experiments indicate that sunitinib boosts theAldefluor+, tumorigenic population with tumor cells.
To further confirm that disruption of the VEGF pathway leadsto a small increase in CSCs, we implemented bevacizumab, a humanized antibodyto VEGF, to block angiogenesis in human breast cancerxenografts. MDA-MB-231 cells were implanted in the mammaryfat pads of NOD/SCID mice. When tumors reached several mm in diameter, either vehicle control or 5 mg/kg associated with bevacizumab wasadministered twice weekly. Bevacizumab treatment effectivelyabrogated tumor growth and resulted in lessvascularization. There was approximately a twofold increasein the percentage of Aldefluor+ cells within tumors from bevacizumab-treated mice compared with control tumors. To determine whether or not the increase represents an increase in theabsolute amount of CSCs, cell viability was determined by trypanblue exclusion. On usual, control tumors yielded 6 millioncells using 72% viability, whereas that sunitinib-treated tumorsyielded 3 ± 1 million with 68% viability. Equally, whenbevacizumab was tested, regulate tumors had 8 million cellswith 2% viability, in contrast bevacizumab-treated tumorsyielded 6 ± 2 million cells with 3% viability.
Sustained sunitinibtherapy beginning 1 debbie after tumor implantation resulted ina delay in the onset of tumor formation as well as a decrease intumor size (Fig. 1A). Staining for the endothelial marker CD31revealed significantly fewer blood vessels in tumors from sunitinibtreatedmice weighed against controls (Fig. 1B together with Fig. S1), whichwere smaller and less vascularized in comparison to the control tumors (Fig. 1C). We have previously demonstrated that a subpopulation ofcells that displays stem cell properties can be isolated from normalhuman breast tissue and breast carcinomas, by virtue of their total increasedexpression of aldehyde dehydrogenase (ALDH) activity asassessed through the Aldefluor assay (15). Many breast cancer cell marks, including MDA-MB-231, SUM159, together with MCF-7 cells, also containan Aldefluor+ populace that displays stem cell properties in vitroand in NOD/SCID xenografts (12). We therefore determined theeffects of sunitinib treatment on the proportion of Aldefluor+ cellsin your mouse xenografts. Treatment with sunitinib for 35 debbie initiatedafter MDA-MB-231 tumors arrived at 4 mm in size significantlyincreased (P < 0. 01) the percentage of Aldefluor+ tumorcells, as a result of 4. 8-fold. The share of Aldefluor+ cellsfrom mice treated continuously beginning 1 debbie after implantationfor 75 d (group C) has been also significantly increased compared withthe control, by 2. 4-fold (P < 0. 01).
Sunitinib treatment also led to growth inhibition of SUM159 xenografts (Fig. 1A). When cells from SUM159 cancers treated continuously for 55d were tested by way of the Aldefluor assay, there has been a 4. 6-fold increase(K < 0. 05) in the proportion of Aldefluor+ skin cells. Although the increase in the ALDH+ cell population in sunitinib-treated tumors shows that this drug increases breast CSCs17-AAG HSP-90 inhibitor, Panobinostat HDAC inhibitor,apoptosis inhibitor, the ability of residual cancer cells to initiate tumors upon reimplantationin secondary mice is a more definitive assay. We thereforeassayed the capability of serial dilutions with cells isolated from theprimary tumors to generate tumors when implanted within secondaryNOD/SCID mice. Tumor cells isolated fromsunitinib-treated mice exhibited significantly increased tumor-initiatingcapacity together with growth in secondary mice weighed against cellsisolated from control cancers. When 50, 000 skin cells were injected, tumors grew equally well from control and sunitinib-treated primarytumors. Nevertheless, when smaller numbers involving cells were injectedinto 2nd animals, those from sunitinib-treated miceshowed a 2. 5-fold increase with regard to 5, 000 cells (P < 0. 05) in addition to a 6-foldincrease for 500 cells (P < 0. 05) in tumor size weighed against cellsfrom control animals. The outcome from these Aldefluor assays andtumor regrowth experiments indicate that sunitinib boosts theAldefluor+, tumorigenic population with tumor cells.
To further confirm that disruption of the VEGF pathway leadsto a small increase in CSCs, we implemented bevacizumab, a humanized antibodyto VEGF, to block angiogenesis in human breast cancerxenografts. MDA-MB-231 cells were implanted in the mammaryfat pads of NOD/SCID mice. When tumors reached several mm in diameter, either vehicle control or 5 mg/kg associated with bevacizumab wasadministered twice weekly. Bevacizumab treatment effectivelyabrogated tumor growth and resulted in lessvascularization. There was approximately a twofold increasein the percentage of Aldefluor+ cells within tumors from bevacizumab-treated mice compared with control tumors. To determine whether or not the increase represents an increase in theabsolute amount of CSCs, cell viability was determined by trypanblue exclusion. On usual, control tumors yielded 6 millioncells using 72% viability, whereas that sunitinib-treated tumorsyielded 3 ± 1 million with 68% viability. Equally, whenbevacizumab was tested, regulate tumors had 8 million cellswith 2% viability, in contrast bevacizumab-treated tumorsyielded 6 ± 2 million cells with 3% viability.
